Check-Cap Ltd (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, an ingestible capsule for the prevention of colorectal cancer, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported research and development expenses at USD2.3m for the three months ended 31 March 2019, compared to USD1.6m for the same period in 2018.
The firm posted an operating loss of USD3.2m for the three months ended 31 March 2019, as against an operating loss of USD2.1m for the same period in 2018.
AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA
Teva reports new ecopipam data showing tic reduction in Tourette syndrome
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Clear Scientific reports positive CS-1103 Phase 2 Results in removing fentanyl from the Body
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
Pfizer's tilrekimig shows significant skin clearance in Phase 2 atopic dermatitis study
Sanofi and Regeneron expand antibody alliance with four next-generation immunology programmes
AFYREN ingredient enables global launch of natural propionic acid skincare product
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
Takeda reports positive Phase 3 psoriasis results for zasocitinib versus deucravacitinib
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets